Wednesday Morning Movers: Gilead Sciences, Myriad Genetics Tumble Following Earnings

By: via Benzinga
Myriad Genetics, Inc. (NASDAQ: MYGN) -15% - Reported Q2 EPS, retirement of President, CEO Meldrum. Downgraded at Credit Suisse and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.